MARINUS PHARMACEUTICALS INC's ticker is MRNS and the CUSIP is 56854Q101. A total of 60 filers reported holding MARINUS PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 1.20 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $46,000 | +2200.0% | 17,925 | +1984.3% | 0.00% | – |
| Q1 2020 | $2,000 | 0.0% | 860 | -52.0% | 0.00% | – |
| Q3 2019 | $2,000 | -85.7% | 1,791 | -61.9% | 0.00% | -100.0% |
| Q4 2018 | $14,000 | +600.0% | 4,698 | +1786.7% | 0.00% | – |
| Q3 2018 | $2,000 | +100.0% | 249 | -31.0% | 0.00% | – |
| Q1 2018 | $1,000 | -92.9% | 361 | -79.0% | 0.00% | -100.0% |
| Q4 2017 | $14,000 | – | 1,719 | – | 0.00% | – |
| Q3 2017 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
| Q2 2017 | $7,000 | +250.0% | 5,201 | +297.3% | 0.00% | – |
| Q1 2017 | $2,000 | -80.0% | 1,309 | -84.2% | 0.00% | -100.0% |
| Q2 2016 | $10,000 | +100.0% | 8,260 | +813.7% | 0.00% | 0.0% |
| Q1 2016 | $5,000 | +150.0% | 904 | +352.0% | 0.00% | – |
| Q3 2015 | $2,000 | -33.3% | 200 | -33.3% | 0.00% | – |
| Q1 2015 | $3,000 | -92.7% | 300 | -92.3% | 0.00% | -100.0% |
| Q4 2014 | $41,000 | +24.2% | 3,908 | -24.5% | 0.00% | 0.0% |
| Q3 2014 | $33,000 | – | 5,173 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 3,977,453 | $15,194,000 | 8.96% |
| Granite Point Capital Management, L.P. | 2,638,321 | $10,078,000 | 0.98% |
| New Leaf Venture Partners, L.L.C. | 342,550 | $1,309,000 | 0.71% |
| 683 Capital Management, LLC | 1,200,000 | $4,584,000 | 0.40% |
| Virtus ETF Advisers LLC | 80,389 | $307,000 | 0.27% |
| Iguana Healthcare Management, LLC | 100,000 | $382,000 | 0.25% |
| THREE BAYS CAPITAL LP | 944,300 | $3,607,000 | 0.25% |
| Granite Point Capital Management, L.P. | 549,900 | $2,101,000 | 0.20% |
| Cormorant Asset Management, LP | 478,111 | $1,826,000 | 0.14% |
| GMT CAPITAL CORP | 2,533,798 | $9,680,000 | 0.12% |